Results 21 to 30 of about 18,115 (178)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

Frontiers in Oncology, 2021
BackgroundNivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure.
Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang   +8 more
doaj   +1 more source

Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). [PDF]

, 2022
AIM Locally advanced rectal cancer (LARC) is an area of unmet medical need with one third of patients dying from their disease. With response to neoadjuvant chemo-radiotherapy being a major prognostic factor, trial SAKK 41/16 assessed potential ...
Cédric Bovet, Joerger, Markus, Ulrich Jaehde, Daniela Bärtschi, Decosterd, Laurent Arthur, Bastian, Sara, Guckenberger, Matthias, Chantal Csajka, Markus Joerger, Csajka, Chantal, Regula Theurillat, von Moos, Roger, Jaehde, Ulrich, Laurent Arthur Decosterd, Largiadèr, Carlo R, Sara Bastian, Jean‐Christophe Prost, Bärtschi, Daniela, Prost, Jean-Christophe, Roger von Moos, Matthias Guckenberger, Eduard Schmulenson, Theurillat, Regula, Carlo R. Largiadèr, Schmulenson, Eduard, Bovet, Cédric   +25 more
core   +2 more sources

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study

Frontiers in Oncology, 2022
BackgroundRegorafenib improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we report the treatment patterns of regorafenib in the third- or late-line setting for mCRC in
Donghao Xu, Yu Liu, Wentao Tang, Lingsha Xu, Tianyu Liu, Yudong Jiang, Shizhao Zhou, Xiaorui Qin, Jisheng Li, Jiemin Zhao, Lechi Ye, Wenju Chang, Wenju Chang, Jianmin Xu, Jianmin Xu   +14 more
doaj   +1 more source

Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis

Cell Death and Disease, 2022
Cholangiocarcinoma (CCA) is a subtype of bile duct cancer usually diagnosed late with a low survival rate and no satisfactorily systemic treatment. Recently, regorafenib has been accepted as a second-line treatment for CCA patients.
Yu-Chan Chang, Chien-Hsiu Li, Ming-Hsien Chan, Ming-Huang Chen, Chun-Nan Yeh, Michael Hsiao   +5 more
doaj   +1 more source

Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib

Dermatology Reports, 2021
Regorafenib is an oral multikinase inhibitor targeting several tyrosine kinase receptors including BRAF and epidermal growth factor receptor (EGFR), and is approved as a third-line treatment for metastatic gastrointestinal stromal tumor (GIST).
Haruhiko Otsuka, Takeshi Fukumoto, Naomi Kiyota, Chihiro Takemori, Haruki Jimbo, Chikako Nishigori   +5 more
doaj   +1 more source

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report [PDF]

, 2015
Ronald Tang,1 Tatiana Kain,2 June Herman,2 Tara Seery1 1Division of Hematology-Oncology, 2Division of Nuclear Medicine and Molecular Imaging, University of California, Irvine, Orange, CA, USA Abstract: Regorafenib, an oral multikinase inhibitor, was ...
Tang, Ronald, Herman, June, Tang R, Kain T, Seery T, Seery, Tara, Herman J, Kain, Tatiana   +7 more
core   +1 more source

A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC

Cancer & Metabolism, 2023
Background Hepatocellular carcinoma (HCC) is a principal type of liver cancer with high incidence and mortality rates. Regorafenib is a novel oral multikinase inhibitor for second-line therapy for advanced HCC.
Huihua Yang, Dahong Chen, Yafei Wu, Heming Zhou, Wenjing Diao, Gaolin Liu, Qin Li   +6 more
doaj   +1 more source

Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells

Frontiers in Oncology, 2021
Combination treatment with tyrosine kinase inhibitors (TKIs) and immunotherapies has shown efficacy in the treatment of multiple cancers, but the immunomodulatory effect of TKIs on the tumor cell phenotype remains unknown in hepatocellular carcinoma (HCC)
Aya Takahashi, Atsushi Umemura, Kota Yano, Shinya Okishio, Seita Kataoka, Keiichiro Okuda, Yuya Seko, Kanji Yamaguchi, Michihisa Moriguchi, Takeshi Okanoue, Yoshito Itoh   +10 more
doaj   +1 more source

Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD

Cells, 2020
The oral multi-target kinase inhibitor regorafenib, which targets the oncogenic receptor tyrosine kinase (RTK), is an effective therapeutic for patients with advanced gastrointestinal stromal tumors or metastatic colorectal cancer.
Kyung-Min Han, Ri Jin Kang, Hyongjun Jeon, Hyun-ju Lee, Ji-Soo Lee, HyunHee Park, Seong Gak Jeon, Kyoungho Suk, Jinsoo Seo, Hyang-Sook Hoe   +9 more
doaj   +1 more source

Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells

Neoplasia: An International Journal for Oncology Research, 2023
Lung cancer is one of the most commonly diagnosed cancers worldwide. Although cisplatin-based chemotherapy regimens serve a pivotal role in non-small cell lung cancer (NSCLC) treatment, drug resistance and serious side effects limited its further ...
Hehuan Sui, Sisi Xiao, Suping Jiang, Siyuan Wu, Haizhen Lin, Liyuan Cheng, Lihua Ye, Qi Zhao, Yun Yu, Lu Tao, Feng-Ming Kong, Xiaoying Huang, Ri Cui   +12 more
doaj   +1 more source